Last reviewed · How we verify
NCT01123538: ProGEP
Progestagen Type in Postmenopausal Hormone Therapy and Blood Gene Expression
Phase 4 trial testing Progesterone in Pharmacogenomics in 40 participants. Status unknown.
1 October 2011
Quick facts
| Lead sponsor | University Hospital of North Norway |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Enrollment | 40 |
| Start date | 1 December 2008 |
| Primary completion | 1 October 2011 |
| Estimated completion | 1 October 2012 |
| Sites | 1 location across Norway |
Drugs / interventions tested
- Progesterone (Progesterone plus HCG) — full drug profile →
- Chlormadinone acetate — full drug profile →
Conditions studied
- Pharmacogenomics — all drugs for Pharmacogenomics →
- Systems Biology — all drugs for Systems Biology →
Sponsor
University Hospital of North Norway
Who can join
Adults 45 to 65, female only, with Pharmacogenomics or Systems Biology. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Whole blood and white blood cells gene expression profiling after 3 months of HT treatment
Time frame: 0 and 3 months after treatment
Sponsor's own description
The purpose of this study is to compare combined postmenopausal hormone therapy natural progesterone to the one containing synthetic progestagen (i.e. chlormadinone acetate) at the blood transcriptome level.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT01123538
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Progesterone
Trials testing the same drug.
- NCT07372495 — Cerclage Plus Progesterone vs Progesterone Alone in Twin Short Cervix · NA · not yet recruiting
- NCT06631547 — Effect of Progesterone Administration on Severely Head Injured Patients · Phase 1 · not yet recruiting
- NCT07162961 — Nintedanib for Improving Reproductive Outcomes in Adenomyosis · Phase 3 · not yet recruiting
- NCT06851754 — Hormone Replacement Therapy in Adolescents With Premature Ovarian Insufficiency · Phase 3 · recruiting
- NCT06928844 — Role of Low Dose Injectable Progesterone in Triggering Ovulation · NA · recruiting
Other University Hospital of North Norway trials
Trials by the same sponsor.
- NCT07343895 — Population-based Atrial Fibrillation Screening in Individuals With NT-proBNP Above Median in the Tromsø Study · NA · recruiting
- NCT07149246 — The Effect of a 6-month Dietitian-tailored Nutrition Intervention to Patients With Critical Illness (DETAIL) · NA · recruiting
- NCT07092904 — Myocardial Infarction Safe Emergency Medicine Accompanying Study: Providing Reperfusion Therapy Within the Recommended T · not yet recruiting
- NCT07530588 — Decentralized Imaging by REmote Computer Tomography for Cerebral Infarct Thrombolysis · NA · recruiting
- NCT06881758 — High Intensity Training for Patients with Anxiety · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01123538 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital of North Norway
- Last refreshed: 2 November 2011
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01123538.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing